BioSpace News Archive

Huami (NYSE: HMI), announced a collaboration with China National Clinical Research Center of Respiratory Disease (NCRCRD) and Guangdong Nanshan Medical Innovation Institute, led by Dr. Nanshan Zhong, to establish a smart wearable joint laboratory.

Masimo (NASDAQ: MASI) announced today the full market release of Masimo SafetyNet™, an innovative, economically scalable cloud-based patient management solution designed to help clinicians care for patients remotely in hospital settings and in non-traditional settings and circumsta

Virtual Medical Care through App and AI-Powered Clinics Limit Exposure to COVID-19

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 19th Annual Needham Virtual Healthcare Conference. The presentation will take place on Wednesday April 15, 2020 at 2:50PM ET. This meeting is being held virtuall

Liepmann and Erickson add invaluable industry expertise to the Board with more than 60 combined years of nutrition and food science experience

PatientWing (www.patientwing.com), a company with the mission of connecting patients with clinical trials, today announced that it has launched covid19studies.org to increase enrollment in COVID-19 clinical trials.

The guide was developed by Ariadne Labs and The Conversation Project with generous support from the Cambia Health Foundation

Enzychem Lifesciences (KOSDAQ: 183490) today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering treating COVID-19 infections and symptoms using EC-18, the Company’s lead compound.

Lawsuit is part of 3M’s national and global efforts to fight price gouging and counterfeiting of N95 respirators used on the frontlines of the fight against COVID-19

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a cohort analysis of 53 patients hospitalized with severe complications of COVID-19 who were treated with the investigational antiviral remdesivir on an individual compassionate use basis.